Lumos Diagnostics Holdings Limited (ASX:LDX)

Market Cap	53.15M
Revenue (ttm)	23.71M
Net Income (ttm)	-8.05M
Shares Out	748.52M
EPS (ttm)	-0.01
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	66,043,289
Average Volume	3,565,023
Open	0.0800
Previous Close	0.0290
Day's Range	0.0670 - 0.0800
52-Week Range	0.0190 - 0.0770
Beta	0.69
RSI	91.80
Earnings Date	Jul 31, 2025

About ASX:LDX

Lumos Diagnostics Holdings Limited develops, manufactures, and commercializes point-of-care diagnostic products for diagnosis and management of infectious diseases in the United States and Australia. Its products include FebriDx, a point-of-care diagnostic test for detecting and differentiating viral and bacterial respiratory infections; and ViraDx, a three-in-one point-of-care test for influenza A, influenza B, and COVID-19. It also offers disposable, Lumos Leelu, and hand-held readers. The company was incorporated in 2018 and is based in Carl...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2018
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: LDX

Financial Performance

In 2024, ASX:LDX's revenue was $11.13 million, an increase of 5.66% compared to the previous year's $10.54 million. Losses were -$8.59 million, -4.22% less than in 2023.

Financial numbers in USD